Provided by Tiger Trade Technology Pte. Ltd.

Kalvista Pharmaceuticals Inc

14.99
+0.08000.54%
Post-market: 14.990.00000.00%16:10 EST
Volume:616.17K
Turnover:9.19M
Market Cap:757.69M
PE:-3.80
High:15.23
Open:14.82
Low:14.23
Close:14.91
52wk High:19.00
52wk Low:9.24
Shares:50.55M
Float Shares:27.81M
Volume Ratio:0.99
T/O Rate:2.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9460
EPS(LYR):-3.6945
ROE:-190.18%
ROA:-60.98%
PB:18.58
PE(LYR):-4.06

Loading ...

KalVista Pharmaceuticals Announces New Clinical Data on EKTERLY® (sebetralstat) for Hereditary Angioedema at AAAAI 2026

Reuters
·
Feb 12

KalVista Pharmaceuticals Grants Stock Options to New Employees

Reuters
·
Feb 03

Kalvista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 03

KalVista’s Pediatric HAE Trial for Sebetralstat Reaches Completion, Setting Up a Key Catalyst for KALV

TIPRANKS
·
Jan 24

Stifel Nicolaus Sticks to Their Buy Rating for KalVista Pharmaceuticals (KALV)

TIPRANKS
·
Jan 09

Kalvista Pharmaceuticals Inc : Needham Raises Target Price to $35 From $32

THOMSON REUTERS
·
Jan 09

KalVista price target raised to $37 from $27 at H.C. Wainwright

TIPRANKS
·
Jan 09

Greenbrier, General Motors And 3 Stocks To Watch Heading Into Friday

Benzinga
·
Jan 09

KalVista Pharmaceuticals Gains on Strong Demand for Genetic-Disorder Treatment

Dow Jones
·
Jan 09

Kalvista Pharmaceuticals Showcases EKTERLY as First Oral On-Demand Therapy for Hereditary Angioedema

Reuters
·
Jan 09

KalVista Pharmaceuticals Reports $49 Million Full-Year 2025 Revenue for EKTERLY Launch

Reuters
·
Jan 09

Kalvista Pharmaceuticals Provides Update on Strong Ekterly® Launch With Preliminary Fourth Quarter and Full Year 2025 Revenue Results

THOMSON REUTERS
·
Jan 09

Kalvista Pharmaceuticals Inc - Ekterly Generates $35 Mln in Q4 Revenue

THOMSON REUTERS
·
Jan 09

KalVista Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
Jan 06

Japan Approves KalVista's EKTERLY as First Oral On-Demand HAE Treatment

Reuters
·
Dec 22, 2025

Kalvista Pharmaceuticals Announces Approval of Ekterly® (Sebetralstat) in Japan, First and Only Oral on-Demand Treatment for Hereditary Angioedema

THOMSON REUTERS
·
Dec 22, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 04, 2025

KalVista Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
Dec 04, 2025

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Benzinga_recent_news
·
Dec 03, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Dec 01, 2025